in our free newsletter.

Thousands benefit from our email every week.

  • Discounts and special offers
  • Subscriber-only articles and interviews
  • Breaking news and trending topics

Already a subscriber?

By signing up, you accept Moneywise's Terms of Use, Subscription Agreement, and Privacy Policy.

Not interested ?

D.R. Horton

Homebuilders recently got a vote of confidence from Buffett himself after the Oracle of Omaha added a few homebuilder stocks to his portfolio, including D.R. Horton (DHI). He seems to be betting on a boom in home construction, which could be justified by the ongoing shortage of housing across North America.

According to a March report from Realtor.com, the U.S. housing market is short 6.5 million single-family units due to a deade of under-building. This gap could begin to close if more households opt for multi-family units and more construction gets underway. That’s where companies like D.R. Horton step in.

Meanwhile, the stock is undervalued—trading at around 10 times earnings per share. Consider placing this cheap, Buffett-backed stock on your radar for a long-term investment.

Meet Your Retirement Goals Effortlessly

The road to retirement may seem long, but with WiserAdvisor, you can find a trusted partner to guide you every step of the way

WiserAdvisor matches you with vetted financial advisors that offer personalized advice to help you to make the right choices, invest wisely, and secure the retirement you've always dreamed of. Start planning early, and get your retirement mapped out today.

Get Started

Eli Lilly

Pharmaceutical giants are usually good long-term bets. That’s because once a drug or treatment from their pipeline is approved, it can generate revenue and profits for decades. Eli Lilly (LLY) recently received approval for Mounjaro, a drug it intends to deploy in the weight loss market. Effectively, the company has entered into competition with Ozempic, which is one of Danish drugmaker Novo Nordisk’s products.

This market could be worth $71 billion by 2032, according to a report by J.P. Morgan stock analyst Richard Vosser cited by Fierce Pharma, with Eli Lilly capturing a significant chunk of it.

That’s just one drug in a broad portfolio. Eli Lilly already has a track record of steady growth and investment in research and development. As a result, the stock has delivered a total return of more than 1,000% over the past 10 years.

An impressive history and promising future should put this stock on your long-term watch list.

Microsoft

Savvy investments and early moves have put Microsoft (MSFT) at the forefront of developments in artificial intelligence. And the company already has a significant stake in the most promising startup in this field: OpenAI.

OpenAI’s products, like ChatGPT, have already been integrated into Microsoft’s software suite. The tech giant also recently secured a nonvoting seat on the startup’s board.

Microsoft recently expanded this advantage by building its own custom AI chip.

It’s too early to say what impact AI will have on our economy in the future. But it seems increasingly likely that Microsoft will play a pivotal role in this future. That’s why long-term investors may want to consider adding this stock to their “forever” watch list.

Follow These Steps if you Want to Retire Early

Secure your financial future with a tailored plan to maximize investments, navigate taxes, and retire comfortably.

Zoe Financial is an online platform that can match you with a network of vetted fiduciary advisors who are evaluated based on their credentials, education, experience, and pricing. The best part? - there is no fee to find an advisor.

About the Author

Vishesh Raisinghani

Vishesh Raisinghani

Freelance Writer

Vishesh Raisinghani is a freelance contributor at MoneyWise. He has been writing about financial markets and economics since 2014 - having covered family offices, private equity, real estate, cryptocurrencies, and tech stocks over that period. His work has appeared in Seeking Alpha, Motley Fool Canada, Motley Fool UK, Mergers & Acquisitions, National Post, Financial Post, and Yahoo Canada.

What to Read Next

Disclaimer

The content provided on Moneywise is information to help users become financially literate. It is neither tax nor legal advice, is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional. We make no representation or warranty of any kind, either express or implied, with respect to the data provided, the timeliness thereof, the results to be obtained by the use thereof or any other matter.